Results for: C_TS4CO_2023日本語出題内容 🐇 C_TS4CO_2023日本語全真模擬試験 🥗 C_TS4CO_2023日本語試験勉強書 🤟 ➡ www.goshiken.com ️⬅️で✔ C_TS4CO_2023日本語 ️✔️を検索して、無料で簡単にダウンロードできますC_TS4CO_2023日本語試験参考書

Phase III trials in neurology – 2018 in review

January 24, 2019

…s ASA 75 mg, clopidogrel 75 mg and dipyridamole 200 mg BID. The primary outcome was the combined incidence and severity of any recurrent stroke (ischaemic or haemorrhagic) or TIA within 90 days. The trial was stopped early. No difference was seen with intensive antiplatelet therapy compared to the other regimens, but the intensive regimen was associated with more bleeding and severe bleeding events. The conclusion was that triple-therapy antiplate…

Record number of FDA drug approvals in 2018

January 9, 2019

…cond drug for Dravet syndrome, Diacomit (stiripentol, Biocodex) for use in combination with clobazam. Diacomit was approved in Canada in 2012 as an add-on to clobazam and valproate in patients with severe myoclonic epilepsy in infancy (SMEI) and Dravet syndrome. Another FDA first was Onpattro (patisiran, Alnylam Pharmaceuticals) – the first small interfering RNA (siRNA) agent and the first therapy to receive approval for the treatment of polyneuro…

Rare cases of stroke reported with alemtuzumab

December 14, 2018

…mas et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e228; free full text at www.ncbi.nlm.nih.gov/pmc/articles/pmid/27213173/). A cytokine storm was reported in the one patient who died of hemorrhagic stroke. Cytokine syndrome may manifest clinically as pyrexia, headache, malaise and urticarial rash, and may be associated with a transient worsening of neurological symptoms (Moreau et al. Brain 1996;119:225-237). The incidence of cytokine release syn…

Improving QoL in patients with schizophrenia

December 5, 2018

…ore relevant in gauging a patient’s life improvement. Finally, there is a need for further treatment research into patients with psychosis comorbid with SUD so we can provide improved outcomes in this complex patient group. Dr. MacEwan is Clinical Professor, Department of Psychiatry, University of British Columbia, Vancouver, Canada….

ECTRIMS 2018 DAILY REPORT – WEDNESDAY EDITION

October 10, 2018

…on therapy, although a delay in treatment was associated with a poorer outcome. The dropout rate was high (64.7%), primarily due to withdrawal of consent and lack of efficacy. Back to top Increased myocardial infarction risk in MS A Canadian epidemiological study reports that the risk of acute myocardial infarction (AMI) is elevated in MS patients compared to the general population (Marrie et al. ECTRIMS 2018; abstract P408). The study used healt…